Effect of Single Dose Intravenous Magnesium Sulfate on Postoperative Analgesic Consumption in Patients Undergoing Laparoscopic Cholecystectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

106 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-27

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study describes a randomized controlled trial designed to evaluate the impact of a single intravenous dose of magnesium sulfate on postoperative analgesic consumption in patients undergoing laparoscopic cholecystectomy. The primary aim is to determine if magnesium sulfate can reduce postoperative morphine usage and its associated side effects.

The study will involve 106 patients (53 per arm), aged 18-65, classified as ASA physical status I or II, who are scheduled for elective laparoscopic cholecystectomy. Participants will be randomly assigned to receive either 30 mg/kg intravenous magnesium sulfate or a placebo (normal saline), alongside standard anesthetic care. Secondary outcomes include pain scores, the time until rescue analgesia is needed, and the monitoring of hemodynamic responses and potential adverse events. Statistical analysis will utilize descriptive statistics, chi-square tests, and t-tests or Mann-Whitney U-tests to compare the two groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efface of Ketamine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy

NCT07248358

Laparoscopic Cholecystectomy Surgery Postoperative Pain Management

COMPLETED PHASE1

A Study of the Effects of Intravenous Magnesium Sulphate on Anaesthesia and Analgesia in Elective General Surgery Patients

NCT05598307

Pain, Postoperative Pain, Acute Pain, Nociceptive +2 more

UNKNOWN NA

The Efface of Lidocaine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy

NCT07248332

Laparoscopic Cholecystectomy Surgery Postoperative Pain Management

COMPLETED PHASE1

Magnesium Sulfate for TAP Analgesia During Laparoscopic Cholecystectomy

NCT02533284

Postoperative Pain

UNKNOWN NA

Esketamine Combined With Magnesium Sulfate for Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholecystectomy

NCT07131033

Laparoscopic Cholecystectomy Alleviate Postoperative Fatigue Syndrome

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study describes a meticulous randomized controlled trial designed to investigate the "Effect of single dose intravenous magnesium sulfate on postoperative analgesic consumption in patients undergoing laparoscopic cholecystectomy." The study addresses a critical clinical need, as laparoscopic cholecystectomy, despite being a minimally invasive procedure, often leads to significant postoperative pain. This pain traditionally necessitates opioid analgesics, which, while effective, come with a host of undesirable side effects such as nausea, vomiting, constipation, dizziness, and even respiratory depression. The study aims to explore multimodal analgesia (MMA) by specifically examining magnesium, a known NMDA receptor antagonist with analgesic properties, as a means to reduce opioid dependency and improve patient recovery.

The central research question revolves around whether a single intravenous dose of magnesium sulfate can effectively reduce postoperative analgesic consumption in this patient population. The null hypothesis posits that intravenous magnesium sulfate will decrease analgesic consumption, while the alternate hypothesis suggests no such effect.

The primary objective is to quantify the reduction in postoperative morphine consumption in the magnesium group compared to the placebo. Secondary objectives are comprehensive, including the evaluation of pain intensity using the Visual Analogue Scale (VAS), the time until patients require rescue analgesia, an assessment of hemodynamic stability, the impact on neuromuscular blockade, and the incidence of any other adverse events.

Methodologically, it will be a parallel, two-arm randomized controlled trial. Eligible participants will be adult patients (18-65 years) classified as ASA Physical status I or II, scheduled for elective laparoscopic cholecystectomy. Stringent exclusion criteria are in place to ensure patient safety and data integrity, covering factors like patient refusal, high BMI, obstructive sleep apnea, significant organ dysfunction, certain medication use, substance abuse, psychiatric illness, specific surgical durations, or conversion to open surgery.

Patients will be randomly assigned to one of two groups: the Magnesium Sulfate Group (M), receiving 30 mg/kg intravenous magnesium sulfate diluted in 100 ml Normal Saline at the induction of anesthesia, or the Normal Saline Group (S), receiving an equivalent volume of Normal Saline. Both groups will also receive standard multimodal analgesia with intravenous Diclofenac (75 mg) and Paracetamol (1 gm) at the time of port closure. Rescue analgesia, in the form of Morphine (3-4 mg), will be administered if a patient's VAS score is ≥ 4. Extensive intraoperative and postoperative monitoring will be conducted to track various physiological parameters and pain-related outcomes. A robust sample size of 117 patients (53 per arm, adjusted for a 10% attrition rate) has been determined to ensure sufficient statistical power (90%) to detect a 30% reduction in morphine use, with a two-sided significance level of 5%. Data analysis will be performed using SPSS, employing descriptive statistics, Chi-square tests for categorical variables, and independent samples t-tests or Mann Whitney U-tests for continuous variables, with a P-value \< 0.05 considered statistically significant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Analgesia; Postoperative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The central research question revolves around whether a single intravenous dose of magnesium sulfate can effectively reduce postoperative analgesic consumption in this patient population.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Triple-blind: not only from participants and administrators, but also from those tasked with analyzing the data after the experiment has concluded. Masking will be done by independent caregivers making the drug or the palcebo (drug) in look alike syringes

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MgSO4(Group: M)

The Magnesium Sulfate Group (M), receiving 30 mg/kg intravenous magnesium sulfate diluted in 100 ml Normal Saline at the induction of anesthesia,

Group Type EXPERIMENTAL

Magnesium Sulfate 30 mg/kg intravenous diluted in 100 ml Normal Saline.

Intervention Type DRUG

Patients will be randomly assigned to one of two groups: the Magnesium Sulfate Group (M), receiving 30 mg/kg intravenous magnesium sulfate diluted in 100 ml Normal Saline at the induction of anesthesia, or the Normal Saline Group (S), receiving an equivalent volume of Normal Saline. Both groups will also receive standard multimodal analgesia with intravenous Diclofenac (75 mg) and Paracetamol (1 gm) at the time of port closure.

Normal Saline (Group: S)

The Placebo Group Group (S) will recieve 100 ml Normal Saline at the induction of anesthesia.

Group Type PLACEBO_COMPARATOR

Magnesium Sulfate 30 mg/kg intravenous diluted in 100 ml Normal Saline.

Intervention Type DRUG

Patients will be randomly assigned to one of two groups: the Magnesium Sulfate Group (M), receiving 30 mg/kg intravenous magnesium sulfate diluted in 100 ml Normal Saline at the induction of anesthesia, or the Normal Saline Group (S), receiving an equivalent volume of Normal Saline. Both groups will also receive standard multimodal analgesia with intravenous Diclofenac (75 mg) and Paracetamol (1 gm) at the time of port closure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium Sulfate 30 mg/kg intravenous diluted in 100 ml Normal Saline.

Patients will be randomly assigned to one of two groups: the Magnesium Sulfate Group (M), receiving 30 mg/kg intravenous magnesium sulfate diluted in 100 ml Normal Saline at the induction of anesthesia, or the Normal Saline Group (S), receiving an equivalent volume of Normal Saline. Both groups will also receive standard multimodal analgesia with intravenous Diclofenac (75 mg) and Paracetamol (1 gm) at the time of port closure.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age - 18 - 65 years, either sex American Society of Anesthesiologists (ASA) Physical status classification system group I and II Elective laparoscopic cholecystectomy

Exclusion Criteria

Patient refusal BMI \> 30 kg/m² OSA Renal, hepatic or cardiovascular dysfunction including cardiac conduction disorders Those on long term calcium channel blockers or receiving magnesium supplements Opioid or analgesic abuse Psychiatric illness Surgical duration \< 1 h \& \> 3 h Lap converted to open

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No